Corona profits over

AstraZeneca: Billions in business with cancer drugs

The British pharmaceutical company AstraZeneca has been able to massively increase its sales and profits with cancer drugs so far this year. However, the company is doing less and less business with the coronavirus vaccine.

Sales of cancer drugs rose by 17 percent to 12.7 billion US dollars (11.88 billion euros) in the first quarter compared to the same period last year, as the British pharmaceutical company announced in Cambridge on Thursday.

The surplus increased by a good fifth to 2.18 billion dollars. According to analyst James Gordon from the bank JPMorgan, AstraZeneca exceeded market expectations at the start of the year. The confirmed annual outlook now appears conservative, according to the expert.

Declines in corona vaccines
Business with drugs for cardiovascular, kidney and metabolic diseases as well as rare diseases also increased. This more than compensated for a significant decline in business relating to vaccines and medicines against coronavirus.